GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eisai Co Ltd (STU:EII) » Definitions » Cyclically Adjusted Price-to-FCF

Eisai Co (STU:EII) Cyclically Adjusted Price-to-FCF : 7.49 (As of Jun. 21, 2024)


View and export this data going back to . Start your Free Trial

What is Eisai Co Cyclically Adjusted Price-to-FCF?

As of today (2024-06-21), Eisai Co's current share price is €36.84. Eisai Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €4.92. Eisai Co's Cyclically Adjusted Price-to-FCF for today is 7.49.

The historical rank and industry rank for Eisai Co's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

STU:EII' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 5.64   Med: 8.44   Max: 14.6
Current: 7.83

During the past years, Eisai Co's highest Cyclically Adjusted Price-to-FCF was 14.60. The lowest was 5.64. And the median was 8.44.

STU:EII's Cyclically Adjusted Price-to-FCF is ranked better than
91.93% of 322 companies
in the Drug Manufacturers industry
Industry Median: 30.14 vs STU:EII: 7.83

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Eisai Co's adjusted free cash flow per share data for the three months ended in Mar. 2024 was €0.273. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €4.92 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eisai Co Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Eisai Co's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eisai Co Cyclically Adjusted Price-to-FCF Chart

Eisai Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.54 8.97 6.52 8.95 7.73

Eisai Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.95 11.54 9.83 8.49 7.73

Competitive Comparison of Eisai Co's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Eisai Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eisai Co's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eisai Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Eisai Co's Cyclically Adjusted Price-to-FCF falls into.



Eisai Co Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Eisai Co's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=36.84/4.92
=7.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eisai Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Eisai Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.273/107.2000*107.2000
=0.273

Current CPI (Mar. 2024) = 107.2000.

Eisai Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.476 98.000 0.521
201409 2.240 98.500 2.438
201412 -0.055 97.900 -0.060
201503 3.349 97.900 3.667
201506 -1.053 98.400 -1.147
201509 2.133 98.500 2.321
201512 1.702 98.100 1.860
201603 3.248 97.900 3.557
201606 -0.871 98.100 -0.952
201609 3.492 98.000 3.820
201612 1.381 98.400 1.505
201703 2.609 98.100 2.851
201706 -1.490 98.500 -1.622
201709 1.287 98.800 1.396
201712 2.171 99.400 2.341
201803 11.259 99.200 12.167
201806 0.737 99.200 0.796
201809 3.677 99.900 3.946
201812 0.503 99.700 0.541
201903 3.355 99.700 3.607
201906 -3.493 99.800 -3.752
201909 0.944 100.100 1.011
201912 1.611 100.500 1.718
202003 7.161 100.300 7.654
202006 -0.233 99.900 -0.250
202009 0.448 99.900 0.481
202012 -1.186 99.300 -1.280
202103 4.795 99.900 5.145
202106 -0.766 99.500 -0.825
202109 8.139 100.100 8.716
202112 -0.158 100.100 -0.169
202203 0.974 101.100 1.033
202206 -0.294 101.800 -0.310
202209 -0.679 103.100 -0.706
202212 -0.343 104.100 -0.353
202303 0.421 104.400 0.432
202306 0.093 105.200 0.095
202309 0.293 106.200 0.296
202312 0.024 106.800 0.024
202403 0.273 107.200 0.273

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eisai Co  (STU:EII) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Eisai Co Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Eisai Co's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Eisai Co (STU:EII) Business Description

Industry
Address
4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of a pharmaceutical business and other businesses. The pharmaceutical business is categorized by region, including Japan, Americas, China, Asia, and Europe, Middle East, and Africa. Eisai also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived by its Japanese pharmaceutical business, followed by its Americas pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.

Eisai Co (STU:EII) Headlines

No Headlines